# Chapter 14 — Software Platform: From Framework to Clinical Tool

> *Part V — Horizons*

---

## 14.1 Introduction

The transition from theoretical framework to clinical adoption requires a software platform that automates the AVBC assessment, provides real-time decision support, and accumulates the calibration data needed for continuous improvement. This chapter describes the architectural design, functional requirements, and implementation roadmap for the AVBC Clinical Platform.

---

## 14.2 Architecture

### 14.2.1 Three-Layer Design

1. **Data Layer:** Imports topographic, aberrometric, and refraction data from standard clinical instruments (Pentacam XML/DICOM, aberrometer exports).
2. **Analysis Layer:** Performs trimodal O-T-B assessment automatically. Calculates MNA, ACEmin, and classifies the patient.
3. **Simulation Layer:** Runs parametric FEM simulations (or reduced-order surrogate models) to predict VR, VT, and Vτ for candidate ring configurations.

### 14.2.2 User Interface

The platform presents:
- **Assessment Dashboard:** O/T/B module classification with visual indicators.
- **Ring Configurator:** Interactive selection of thickness, arc, and symmetry profile with real-time VR/VT/Vτ predictions.
- **Comparison View:** AVBC recommendation vs. nomogram recommendation side by side.
- **Postoperative Module:** AVBC-CI calculation and personal calibration curve visualization.

---

## 14.3 Functional Requirements

### 14.3.1 Minimum Viable Product (MVP)
1. Automated O Module classification from aberrometry data.
2. MNA calculation from posterior elevation data.
3. Vector-based ring recommendation engine.
4. AVBC-CI calculator for postoperative feedback.

### 14.3.2 Full Platform
5. Patient-specific FEM simulation.
6. Reduced-order model for real-time predictions.
7. Multi-surgeon calibration database.
8. Clinical trial data management.

---

## 14.4 Reduced-Order Models

Full FEM simulation requires minutes to hours. For clinical use, reduced-order surrogate models can provide predictions in seconds:

1. **Polynomial Response Surfaces:** Fit parametric relationships (VR = f(thickness, arc, c, k₁)) from the FEM database.
2. **Neural Network Surrogates:** Train on the 377-simulation database to predict VR, VT, Vτ from input parameters.
3. **Gaussian Process Models:** Provide uncertainty quantification alongside point predictions.

---

## 14.5 Regulatory Considerations

The AVBC platform, as a clinical decision-support tool, would require regulatory clearance as a medical device software (SaMD):
- **FDA:** 510(k) or De Novo classification for ophthalmic planning software.
- **CE Marking:** Medical Device Regulation (MDR) Class IIa.
- **Clinical evidence:** Prospective validation data (Chapter 13) is required.

---

## 14.6 Implementation Roadmap

| Phase | Timeline | Deliverable |
|---|---|---|
| 1. MVP Development | Months 1–6 | O/T/B classifier + ring recommendation engine |
| 2. FEM Integration | Months 6–12 | Parametric FEM pipeline + reduced-order models |
| 3. Clinical Pilot | Months 12–24 | Deployment in 3–5 clinical sites, data collection |
| 4. Regulatory Submission | Months 24–36 | 510(k) / CE marking application |
| 5. Commercial Release | Months 36–48 | Market availability |

---

## 14.7 Summary

The AVBC Clinical Platform translates the theoretical framework into a practical clinical tool through automated trimodal assessment, real-time simulation predictions, and continuous calibration feedback. The platform architecture supports progressive sophistication from a rule-based MVP to a patient-specific FEM simulator, with regulatory clearance as the gating milestone.

---

## References
1. FDA. Software as a Medical Device (SaMD): Clinical Evaluation. 2017.
2. Kling S, Marcos S. FEM of ICRS in a hyperelastic cornea. *IOVS*. 2013;54(1):881–889.
